- authorisedTherapeutic exploratory (Phase II)
Development of a Short-Acting GH Suppression Test with subcutaneous short action Pasireotide (PAT) for Predicting Long-Term Response to Pasireotide LAR in Patients with Acromegaly
This study tests whether a quick injection can show if a medicine called pasireotide will work for someone with acromegaly. Doctors measure growth hormone levels two to three hours after the injection. This may help people avoid months of trying a long-term treatment that might not suit them.
Spain - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly
This study tests a new injection called ALXN2420 for adults with acromegaly. Researchers want to see if adding it to usual hormone treatments helps lower a key body protein called IGF-1 more effectively, while checking its safety and side effects over 15 weeks of treatment.
Lithuania · Romania · Denmark - recruitingTherapeutic exploratory (Phase II)
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE)
This study looks at a new medicine called paltusotine for people with acromegaly. It's a long-term study to see how safe the medicine is and if it works well over time, especially noting any side effects people might have.
Hungary · Greece · Germany - recruitingTherapeutic confirmatory (Phase III)
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands
This study is looking into a new tablet called paltusotine for people with acromegaly, a condition where your body makes too much growth hormone. It wants to see if this tablet can help keep hormone levels normal, similar to current long-acting treatments.
Belgium · France · Hungary - recruitingTherapeutic confirmatory (Phase III)
A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly (PATHFNDR-2)
This study, called PATHFNDR-2, is for adults with acromegaly who haven't started medication yet. It's testing a new drug, Paltusotine, against a dummy pill to see if it can help control hormone levels (IGF-1). Researchers want to find out if Paltusotine is safe and effective.
Germany · France · Hungary - recruitingHuman Pharmacology (Phase I)- First administration to humans
A single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3813, a growth hormone antagonist, in healthy subjects
This early-stage study is looking at a new medicine called AZP-3813 for a condition called acromegaly. Researchers want to see if it's safe, how the body handles it, and if it has the desired effects in healthy people who don't have acromegaly yet. It's the first time it’s been given to humans.
Netherlands - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, open-label, single-arm, multi-center trial to assess the long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly
This study looks at a new way to give medicine for acromegaly, a condition caused by too much growth hormone. We want to see how safe this new treatment is over a long time and if it helps control the condition effectively. It's for adults with acromegaly.
Hungary · Germany · Spain - active not recruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
This study is testing a new medicine, paltusotine, for people with acromegaly, a rare condition causing too much growth hormone. It's a pill being compared to a dummy pill to see if it's safe and helps improve symptoms.
United States · Argentina · Brazil - active not recruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
This study is looking at a new medicine called paltusotine for people with acromegaly. It wants to see if this oral medicine is safe and helps control the condition in those who have already been treated with other common acromegaly medicines.
United States · Argentina · Belgium - recruiting
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
This study looks at how a treatment called Octreotide subcutaneous depot works for people with acromegaly in their daily lives. We want to understand its long-term effects and how safe it is over two years, helping us learn more about this medication for this specific condition.
Germany · United Kingdom - recruiting
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
This study aims to find new genes that cause rare growths (tumours) in the pituitary gland, which is at the base of your brain. These tumours can lead to conditions like acromegaly or gigantism. Researchers hope to learn how these genes work to develop better ways to understand and treat these conditions.
United Kingdom - active not recruitingPHASE2
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
This study looks at a new oral medicine called paltusotine for people with acromegaly. It checks how safe and effective it is over a long time for those who have already tried it in previous studies. The aim is to see if it continues to help manage the condition.
United States · Brazil · Germany - recruitingPHASE3
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
This study is testing a new medicine, Debio 4126, for people with acromegaly, a hormone disorder, who are already taking similar treatments. We want to see if Debio 4126 can help keep their hormone levels stable compared to a dummy drug.
United States · Austria · Belgium